Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.38 |
| ▸ | CTSE | P14091 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | MARK3 | P27448 | 3/20 | 0.36 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150359 | 0.73 | OPRL1 (0.43) | BACE1CTSECYP3A4CYP2C19 | |
| SCHEMBL1149527 | 0.70 | MARK3 (0.37) | CYP3A4CYP2C19MARK3SCN9A | |
| SCHEMBL12433042 | 0.69 | CRHR1 (0.55) | BACE1SCN9A | |
| SCHEMBL1149632 | 0.65 | ALDH1A1 (0.48) | MARK3MARK4 | |
| SCHEMBL3720300 | 0.63 | FFAR4 (0.32) | — | |
| SCHEMBL15579012 | 0.61 | MARK3 (0.41) | BACE1MARK3MARK4 | |
| SCHEMBL15578995 | 0.61 | MARK3 (0.41) | MARK3MARK4 | |
| SCHEMBL1149572 | 0.60 | KDR (0.48) | — | |
| SCHEMBL31074695 | 0.59 | CDK2 (0.42) | MARK3MARK4 | |
| SCHEMBL2482302 | 0.58 | FFAR4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580813-B2 | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| EP-2240482-B1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039861-A1 | CYCLIC AZAINDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | REN, PM20D2, CDK20 | BACE1 2632/4885CTSE 469/4885CYP3A4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.